Literature DB >> 25469257

Investigation of the functional single-nucleotide polymorphisms in the BCRP transporter and susceptibility to colorectal cancer.

Fatih M Sari1, Hakan T Yanar2, Gul Ozhan1.   

Abstract

Breast cancer resistance protein (BCRP) protects tissues by actively transporting xenobiotics and their metabolites out of the cells. BCRP is expressed in the apical membrane of normal intestinal and colonic epithelium. The BCRP substrates include a number of structurally unrelated compounds, such as drugs, pesticides, carcinogens and endogenous compounds. Although the functional and common BCRP alleles, 34G>A and 421C>A, are shown to vary by ethnicity, their potential mechanism has not been adequately described with regards to affecting the susceptibility to colorectal cancer. The present study aimed to evaluate the effects of the BCRP variants on the susceptibility to colorectal cancer and to predict the individual responses to xenobiotics transferred by BCRP. BCRP 421C>A was significantly associated with the colorectal cancer risk (odds ratio, 16.12; P=0.005). These findings are the first results of BCRP allele distributions in the Turkish population and provide an understanding of the correlation between therapeutic approaches and etiology of colorectal cancer.

Entities:  

Keywords:  BCRP variants; colorectal cancer; genetic polymorphisms

Year:  2014        PMID: 25469257      PMCID: PMC4251126          DOI: 10.3892/br.2014.383

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  44 in total

1.  Role of the breast cancer resistance protein (ABCG2) in drug transport.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2005-05-11       Impact factor: 4.009

Review 2.  The staging of colorectal cancer: 2004 and beyond.

Authors:  Carolyn C Compton; Frederick L Greene
Journal:  CA Cancer J Clin       Date:  2004 Nov-Dec       Impact factor: 508.702

Review 3.  Role of ABCG2/BCRP in biology and medicine.

Authors:  P Krishnamurthy; J D Schuetz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

4.  Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.

Authors:  Christoph G Dietrich; Ann-Kathrin Vehr; Ina V Martin; Nikolaus Gassler; Timo Rath; Elke Roeb; Johannes Schmitt; Christian Trautwein; Andreas Geier
Journal:  Int J Cancer       Date:  2011-05-05       Impact factor: 7.396

5.  Functional analysis of SNPs variants of BCRP/ABCG2.

Authors:  Chihiro Kondo; Hiroshi Suzuki; Masaya Itoda; Shogo Ozawa; Jun-ichi Sawada; Daisuke Kobayashi; Ichiro Ieiri; Kazunori Mine; Kenji Ohtsubo; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

6.  Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups.

Authors:  Phillip Müller; Nava Asher; Maya Heled; Sara Bar Cohen; Angela Risch; Deborah Rund
Journal:  Leuk Res       Date:  2008-01-18       Impact factor: 3.156

7.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

Review 8.  The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation.

Authors:  A Haimeur; G Conseil; R G Deeley; S P C Cole
Journal:  Curr Drug Metab       Date:  2004-02       Impact factor: 3.731

9.  The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature.

Authors:  Pin Chen; Lin Zhao; Peng Zou; Haitao Xu; Ailin Lu; Peng Zhao
Journal:  BMC Cancer       Date:  2012-09-01       Impact factor: 4.430

10.  Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

Authors:  Vibeke Andersen; Mette Ostergaard; Jane Christensen; Kim Overvad; Anne Tjønneland; Ulla Vogel
Journal:  BMC Cancer       Date:  2009-11-21       Impact factor: 4.430

View more
  5 in total

1.  Study of Breast Cancer Resistance Protein ABCG2 C421A Single Nucleotide Polymorphism RS2231142 in Multiple Myeloma.

Authors:  Hadeer Aly Abbassy; Mayada Aly Moussa; Rahma Mohamed Abd Elmoniem; Salma Alaa Eldin Imbaby
Journal:  Indian J Hematol Blood Transfus       Date:  2022-02-01       Impact factor: 0.915

2.  Polymorphisms of xenobiotic-metabolizing and transporter genes, and the risk of gastric and colorectal cancer in an admixed population from the Brazilian Amazon.

Authors:  Amanda Nazaré Cohen Lima de Castro; Marianne Rodrigues Fernandes; Darlen Cardoso de Carvalho; Tatiane Piedade de Souza; Juliana Carla Gomes Rodrigues; Roberta Borges Andrade; Antonio Andre Conde Modesto; Sidney Santos; Paulo Pimentel Assumpção; Ney Pereira Carneiro Dos Santos
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

3.  The contribution of ABCG2 G34A and C421A polymorphisms to multiple myeloma susceptibility.

Authors:  Katarzyna Niebudek; Ewa Balcerczak; Marek Mirowski; Jacek Pietrzak; Izabela Zawadzka; Marta Żebrowska-Nawrocka
Journal:  Onco Targets Ther       Date:  2019-02-27       Impact factor: 4.147

4.  An 8‑gene signature predicts the prognosis of cervical cancer following radiotherapy.

Authors:  Fei Xie; Dan Dong; Na Du; Liang Guo; Weihua Ni; Hongyan Yuan; Nannan Zhang; Jiang Jie; Guomu Liu; Guixiang Tai
Journal:  Mol Med Rep       Date:  2019-07-29       Impact factor: 2.952

5.  Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease.

Authors:  Aleksandr B Shek; Ravshanbek D Kurbanov; Guzal J Abdullaeva; Aleksandr V Nagay; Shavkat U Hoshimov; Ulugbek I Nizamov; Adolat V Ziyaeva; Rano B Alieva
Journal:  Arch Med Sci Atheroscler Dis       Date:  2017-10-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.